Live feed07:30:00·179dPRReleasevia QuantisnowActinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor IndicationsByQuantisnow·Wall Street's wire, on your screen.ATNM· Actinium Pharmaceuticals Inc. (Delaware)Health Care